Am J Epidemiol 2002; 156:211-218.
Copyright © 2002 by the
Johns Hopkins Bloomberg School of Public Health
ORIGINAL CONTRIBUTIONS |
Changes in the Incidence and Predictors of Wasting Syndrome Related to Human Immunodeficiency Virus Infection, 1987–1999
1 Department of Social and Preventive Medicine, School of Medicine and Biological Sciences, University at Buffalo, Buffalo, NY.
2 Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD.
3 School of Medicine, Johns Hopkins University, Baltimore, MD.
4 Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA.
5 Schools of Public Health and Medicine, University of California, Los Angeles, CA.
6 Feinberg School of Medicine, Northwestern University, Evanston, IL.
The authors examined the impact of potent antiretroviral therapy (ART) on the diagnosis of wasting syndrome in the Multicenter AIDS Cohort Study. Study time was divided into the periods 1988–1990, 1991–1993, 1994–1995, and 1996–1999 to correspond to different treatment eras. The proportion of acquired immunodeficiency syndrome diagnoses in which wasting was present increased from 5% in 1988–1990 to 7.1% in 1991–1993, 7.7% in 1994–1995, and 18.9% in 1996–1999. The incidence of wasting per 1,000 person-years increased from 7.5 in 1988–1990 to 14.4 in 1991–1993 and 22.1 in 1994–1995; it decreased to 13.4 in 1996–1999. Fewer patients with wasting had low hemoglobin and hematocrit levels and reported oral thrush in 1996–1999 than in any other period. Analysis of change in body mass index (weight (kg)/height (m)2) after wasting showed a faster return to prewasting levels in 1994–1995 and 1996–1999 than in earlier periods. Case-control analysis showed that wasting prior to 1996 was weakly associated with fatigue (p = 0.10), low hemoglobin (p = 0.11), and CD4-positive T-lymphocyte count (p = 0.04). During 1996–1999, wasting was weakly associated with diarrhea (p = 0.05) and potent ART (p = 0.097). Predictors of wasting have changed with potent ART. Further research is needed to determine whether lipodystrophy may be misdiagnosed as wasting syndrome. Am J Epidemiol 2002;156:211–18.
acquired immunodeficiency syndrome; AIDS-related opportunistic infections; anti-HIV agents; body mass index; disease progression; HIV; HIV protease inhibitors; HIV wasting syndrome
Abbreviations: Abbreviations: AIDS, acquired immunodeficiency syndrome; ART, antiretroviral therapy; HIV, human immunodeficiency virus; NRTI, nucleoside reverse transcriptase inhibitor.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  F. R Sattler, N. Rajicic, K. Mulligan, K. E Yarasheski, S. L Koletar, A. Zolopa, B. Alston Smith, R. Zackin, B. Bistrian, and for the ACTG 392 Study Team Evaluation of high-protein supplementation in weight-stable HIV-positive subjects with a history of weight loss: a randomized, double-blind, multicenter trial Am. J. Clinical Nutrition, November 1, 2008; 88(5): 1313 - 1321. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. DeJesus, B. M. Rodwick, D. Bowers, C. J. Cohen, and D. Pearce Use of Dronabinol Improves Appetite and Reverses Weight Loss in HIV/AIDS-Infected Patients J Int Assoc Physicians AIDS Care (Chic Ill), June 1, 2007; 6(2): 95 - 100. [Abstract] [PDF]
|
|
|
|
 |
|
 K. Mulligan, R. Zackin, J. H. Von Roenn, M. A. Chesney, M. J. Egorin, F. R. Sattler, C. A. Benson, T. Liu, T. Umbleja, S. Shriver, et al. Testosterone Supplementation of Megestrol Therapy Does Not Enhance Lean Tissue Accrual in Men with Human Immunodeficiency Virus-Associated Weight Loss: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 563 - 570. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Tinmouth, G. Kandel, G. Tomlinson, S. Walmsley, A. H. Steinhart, and R. Glazier The Effect of Dairy Product Ingestion on Human Immunodeficiency Virus-Related Diarrhea in a Sample of Predominantly Gay Men: A Randomized, Controlled, Double-blind, Crossover Trial. Arch Intern Med, June 12, 2006; 166(11): 1178 - 1183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Villamor, E. Saathoff, K. Manji, G. Msamanga, D. J Hunter, and W. W Fawzi Vitamin supplements, socioeconomic status, and morbidity events as predictors of wasting in HIV-infected women from Tanzania Am. J. Clinical Nutrition, October 1, 2005; 82(4): 857 - 865. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Mulligan, R. Zackin, R. A. Clark, B. Alston-Smith, T. Liu, F. R. Sattler, T. B. Delvers, J. S. Currier, and for the AIDS Clinical Trials Group 329 Study Team Effect of Nandrolone Decanoate Therapy on Weight and Lean Body Mass in HIV-Infected Women With Weight Loss: A Randomized, Double-blind, Placebo-Controlled, Multicenter Trial Arch Intern Med, March 14, 2005; 165(5): 578 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Heckmann, C. Waltzinger, P. Jolicoeur, M. Dreano, M. H. Kosco-Vilbois, and Y. Sagot IKK2 Inhibitor Alleviates Kidney and Wasting Diseases in a Murine Model of Human AIDS Am. J. Pathol., April 1, 2004; 164(4): 1253 - 1262. [Abstract] [Full Text] [PDF]
|
|